Találati lista | Tudóstér

001-es BibID:	BIBFORM067415
035-os BibID:	(WoS)000392425200005 (Scopus)84991585385
Első szerző:	Agca, R.
Cím:	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update / R. Agca, S. C. Heslinga, S. Rollefstad, M. Heslinga, I. B. McInnes, M. J. L. Peters, T. K. Kvien, M. Dougados, H. Radner, F. Atzeni, J. Primdahl, A. Södergren, S. Wallberg Jonsson, J. van Rompay, C. Zabalan, T. R. Pedersen, L. Jacobsson, K. de Vlam, M. A. Gonzalez-Gay, A. G. Semb, G. D. Kitas, Y. M. Smulders, Z. Szekanecz, N. Sattar, D. P. M. Symmons, M. T. Nurmohamed
Dátum:	2017
ISSN:	0003-4967
Megjegyzések:	Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Annals Of The Rheumatic Diseases. - 76 : 1 (2017), p. 17-28. -
További szerzők:	Heslinga, S. C. Rollefstad, S. Heslinga, M. McInnes, I. B. Peters, M. J. L. Kvien, Tore K. Dougados, Maxime Radner, H. Atzeni, F. Primdahl, Jette Södergren, A. Wallberg Jonsson, S. van Rompay, J. Zabalan, C. Pedersen, T. R. Jacobsson, L. de Vlam, K. Gonzalez-Gay, Miguel A. Semb, Anne Grete Kitas, George Smulders, Yvo M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Symmons, D. P. M. Nurmohamed, Michael T.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM100160
035-os BibID:	(WOS)000750946900001 (Scopus)85125531096
Első szerző:	Drosos, George C.
Cím:	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome / Drosos George C., Vedder Daisy, Houben Eline, Boekel Laura, Atzeni Fabiola, Badreh Sara, Boumpas Dimitrios T., Brodin Nina, Bruce Ian N., González-Gay Miguel Ángel, Jacobsen Sren, Kerekes György, Marchiori Francesca, Mukhtyar Chetan, Ramos-Casals Manuel, Sattar Naveed, Schreiber Karen, Sciascia Savino, Svenungsson Elisabet, Szekanecz Zoltan, Tausche Anne-Kathrin, Tyndall Alan, van Halm Vokko, Voskuyl Alexandre, Macfarlane Gary J., Ward Michael M., Nurmohamed Michael T., Tektonidou Maria G.
Dátum:	2022
ISSN:	0003-4967
Megjegyzések:	Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Methods Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion. Results Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or uratelowering therapy in gout has been associated with CVR lowering. Conclusion These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Annals Of The Rheumatic Diseases. - 81 : 6 (2022), p. 768-779. -
További szerzők:	Vedder, Daisy Houben, Eline Boekel, Laura Atzeni, Fabiola Badreh, Sara Boumpas, Dimitrios Brodin, Nina Bruce, Ian N. Gonzalez-Gay, Miguel A. Jacobsen, Sren Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Marchiori, Francesca Mukhtyar, Chetan Ramos-Casals, Manuel Sattar, Naveed Schreiber, Karen Sciascia, Savino Svenungsson, Elisabet Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tausche, Anne-Kathrin Tyndall, Alan van Halm, Vokko Voskuyl, Alexandre Macfarlane, Gary J. Ward, Michael M. Nurmohamed, Michael T. Tektonidou, Maria G.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM015844
Első szerző:	Peters, M. J. L.
Cím:	EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis / Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., Semb, A., Sidiropoulos, P., Kitas, G., Smulders, Y. M., Soubrier, M., Szekanecz, Z., Sattar, N., Nurmohamed, M. T.
Dátum:	2010
ISSN:	1468-2060 (Electronic)
Megjegyzések:	To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). METHODS: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing nine European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's "standardised operating procedures", the multidisciplinary steering committee formulated evidence-based and expert opinion-based recommendations for CV risk screening and management in patients with inflammatory arthritis. RESULTS: Annual CV risk assessment using national guidelines is recommended for all patients with RA and should be considered for all patients with AS and PsA. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk. CONCLUSIONS: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA, on the other, as evidence for an increased CV risk is most compelling for RA.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Anti-Inflammatory Agents, Non-Steroidal/therapeutic use Antihypertensive Agents/therapeutic use Arthritis, Psoriatic/complications Arthritis, Rheumatoid/complications Cardiovascular Diseases/etiology/prevention & control Cholesterol/blood Drug Administration Schedule Evidence-Based Medicine/methods Female Glucocorticoids/administration & dosage Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use Male Risk Management/methods Spondylitis, Ankylosing/*complications
Megjelenés:	Annals of the Rheumatic Diseases. - 69 : 2 (2010), p. 325-331. -
További szerzők:	Symmons, D. P. M. McCarey, D. Dijkmans, B. A. C. Nicola, P. Kvien, Tore K. McInnes, I. B. Haentzschel, H. Gonzalez-Gay, Miguel A. Provan, S. Semb, A. Sidiropoulos, P. Kitas, George Smulders, Yvo M. Soubrier, M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Nurmohamed, Michael T.
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat elektronikus változat
Borító:
Saját polcon: